Adagene (ADAG) Projected to Post Earnings on Wednesday

Key Points

• Adagene is expected to report Q2 2026 results on September 2, with analysts forecasting a loss of $0.22 per share and revenue of approximately $17.5 million.
• Shares opened at $3.82 and have traded between $1.30 and $4.85 over the past year. Analysts maintain a consensus “Moderate Buy” rating with a $10 price target, although ratings range from Strong Buy to Sell.
• CEO Peter Luo recently bought 22,966 shares, increasing his position by 51%; insiders own 21.2% of the company, while institutional investors hold 9.51%.

Adagene (NASDAQ:ADAG - Get Free Report) is anticipated to issue its Q2 2026 resultson Wednesday, September 2nd. Analysts expect Adagene to announce earnings of ($0.22) per share and revenue of $17.50 million for the quarter. Parties are encouraged to explore the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Adagene Trading Down 2.1%

ADAG opened at $3.82 on Wednesday. The business's fifty day simple moving average is $3.89 and its 200 day simple moving average is $3.68. Adagene has a 52 week low of $1.30 and a 52 week high of $4.85. The company has a quick ratio of 3.07, a current ratio of 5.02 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

ADAG has been the subject of a number of analyst reports. Guggenheim reissued a "buy" rating and issued a $10.00 price objective on shares of Adagene in a research report on Tuesday, July 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Adagene in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $10.00.

Insider Buying and Selling

In related news, CEO Peter Luo purchased 22,966 shares of the business's stock in a transaction on Tuesday, August 4th. The shares were bought at an average price of $3.65 per share, with a total value of $83,825.90. Following the completion of the purchase, the chief executive officer directly owned 67,966 shares in the company, valued at approximately $248,075.90. This trade represents a 51.04% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have purchased a total of 25,245 shares of company stock worth $92,344 over the last ninety days. Corporate insiders own 21.20% of the company's stock.

Institutional Trading of Adagene

Several institutional investors have recently made changes to their positions in the stock. Marex Group plc purchased a new position in shares of Adagene in the 2nd quarter worth $47,000. SmartHarvest Portfolios LLC acquired a new position in Adagene in the fourth quarter valued at $73,000. Citadel Advisors LLC purchased a new stake in Adagene during the third quarter valued at about $80,000. Finally, Exome Asset Management LLC purchased a new stake in Adagene during the fourth quarter valued at about $2,004,000. 9.51% of the stock is owned by hedge funds and other institutional investors.

About Adagene

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene's pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene's research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source